Abstract
In this issue of Blood, Zhao et al explored the role of low doses of the histone deacetylase inhibitor (HDACi) chidamide in restoring immune tolerance in patients with immune thrombocytopenia (ITP).1.
Cite
CITATION STYLE
APA
Neunert, C. E., & Lambert, M. P. (2019, February 14). More than one pathway: Novel treatment for ITP. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2018-12-892778
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free